Gore Range Capital

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

AOA, based in Boston, New York, and London, is a female-led company focused on developing innovative cancer diagnostics specifically for women's health. The company is dedicated to creating the first accurate early-stage liquid biopsy test for ovarian cancer, which aims to enhance clinical practices, reduce patient mortality, and offer cost savings for healthcare payers. Utilizing an artificial intelligence-enabled platform, AOA's technology analyzes tumor marker gangliosides to facilitate the early detection of ovarian cancer. This approach not only helps healthcare providers implement more effective treatment strategies but also ensures that patients can access life-saving treatments sooner and at a more affordable cost.

Palvella Therapeutics, based in Wayne, Pennsylvania, is a clinical-stage biopharmaceutical company established in 2015. It focuses on developing and commercializing targeted therapies for serious and rare genetic skin diseases, specifically genodermatoses. The company's lead product, QTORIN, is a specialized anhydrous gel designed to deliver active ingredients effectively into the skin, addressing the underlying causes of various dermatological conditions. Palvella's pipeline includes candidates aimed at treating microcystic lymphatic malformations and cutaneous venous malformations, utilizing its proprietary QTORIN platform to offer innovative solutions for underserved patient populations.

Validic, Inc. is a technology company specializing in a cloud-based platform that collects and manages mobile health data from various internet-enabled applications and devices. Founded in 2010 and based in Durham, North Carolina, Validic connects healthcare organizations with over 400 clinical and consumer devices, allowing for the integration of patient-recorded data into clinical workflows. Its primary offerings include Validic Solution, which links digital health data to healthcare providers; Validic Connect, which facilitates access to a broader range of clinical and consumer applications; and Validic Mobile, designed for data collection from health apps and in-home devices. The company serves a diverse clientele, including wellness companies, healthcare providers, pharmaceuticals, and health plans, with the goal of enhancing the quality of human life through actionable health data.

Eirion Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of advanced prescription products for aesthetic dermatology. The company's product pipeline includes treatments aimed at addressing various conditions such as wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. Eirion is committed to meeting significant unmet clinical needs within the field, with plans to explore additional indications in the future. Through its innovative approach, Eirion Therapeutics aims to provide effective solutions for both physicians and patients dealing with aesthetic concerns.

Dorsata, Inc. is a healthcare technology company based in Arlington, Virginia, that specializes in creating an online platform for clinical care paths. Founded in 2011, Dorsata enables healthcare providers to enhance decision-making by offering tools that allow clinicians to build, share, and implement workflows known as care pathways. These pathways are designed to improve collaboration among healthcare teams and facilitate efficient documentation and order entry. By leveraging data and best practices, Dorsata aims to transform healthcare delivery with a focus on cost reduction and quality improvement. Additionally, the company has developed a prenatal record platform that helps manage electronic health records, providing a user-friendly experience and a rules engine to create tailored care plans for patients throughout their pregnancy journey.

Paradigm Diagnostics specializes in advanced cancer diagnostics and biomarker-driven clinical trials, aiming to enhance treatment options for cancer patients. Utilizing next-generation sequencing and comprehensive biomarker analysis, Paradigm assesses the genomic and proteomic characteristics of individual tumors. This information allows for a detailed understanding of the specific cancer pathways involved and the potential therapies tailored to each patient's unique tumor profile. By focusing on personalized medicine, Paradigm empowers healthcare providers to offer targeted treatment strategies, ultimately improving patient outcomes in cancer care.

CoreMedica Laboratories Inc. specializes in the development of blood serum separation and transportation containers designed for various applications, including corporate wellness, epidemiological research, pharmaceutical studies, clinical trials monitoring, and insurance underwriting. Founded in 2010 and headquartered in Lee's Summit, Missouri, the company offers micro and dried blood collection and analysis tools and services. All testing of samples is conducted in its laboratory, which is accredited by the College of American Pathologists (CAP) and certified by the Clinical Laboratory Improvement Amendments (CLIA).

xMD Diagnostics, based in Annapolis, Maryland, specializes in biotechnology within the healthcare sector. The company develops molecular diagnostics tools that use high-throughput microdissection technology to improve cancer diagnosis and management. These tools are designed to isolate, procure, and enrich cells of interest from biopsy and other specimen samples. This process facilitates various downstream analyses, including PCR, genomic or proteomic testing, and next-generation sequencing. By enhancing the capabilities of clinical and research laboratories, xMD Diagnostics supports pathologists, oncologists, and other healthcare professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Claret Medical, Inc. is a medical device company specializing in cerebral vascular protection systems designed to mitigate the risk of stroke during transcatheter aortic valve implantation and other endovascular procedures. Established in 2009 and headquartered in Santa Rosa, California, the company's flagship products include the Claret Medical Sentinel Cerebral Protection System and the Claret Medical Montage, both of which serve as embolic protection devices. These systems utilize small catheters, which are inserted through an artery in the patient's arm and positioned near the heart, to capture and remove embolic debris that may be dislodged during procedures. By preventing this debris from entering the cerebral vascular system, Claret Medical's products aim to enhance patient safety during high-risk cardiovascular interventions. The company operates as a subsidiary of Boston Scientific Corporation.

Medikly, Inc. is a digital marketing platform that assists healthcare marketers in effectively reaching and engaging physicians. Founded in 2009 and based in Jersey City, New Jersey, the company offers a comprehensive solution that allows pharmaceutical brands to form deeper connections with physicians by leveraging actionable insights derived from physician intelligence. Medikly's platform serves as an operating system for healthcare marketers, enabling them to continuously collect, analyze, and manage data from various digital channels. In addition to its core platform, Medikly provides services such as campaign execution, modification, and measurement, along with consulting, support, and training, all aimed at enhancing the efficiency of marketing efforts in the healthcare sector.

NovaScan, Inc. is a company dedicated to the development and manufacturing of innovative cancer detection devices. Founded by the former Dean of the Engineering School at the University of Wisconsin Milwaukee, NovaScan specializes in a non-invasive detection platform that utilizes Cole relaxation frequency technology for the identification and stratification of various cancers. Its product line includes MarginScan for skin cancer detection, BiopsyScan for breast biopsy procedures, FastScan Probe for breast cancer identification, and additional technologies that facilitate electrical mammograms and the detection of multiple cancer types. The company, incorporated in 2001 and headquartered in Chicago, Illinois, focuses on improving patient outcomes and reducing healthcare costs through its rapid, accurate diagnostic solutions, which do not require extensive capital equipment or are limited by size. NovaScan's technologies are designed to enhance minimally invasive procedures and optimize therapeutic dosing within tumors, reflecting its commitment to advancing cancer care.

Conversa Health, Inc. specializes in patient relationship management solutions aimed at enhancing communication between patients and healthcare teams. The company's flagship offering, the Conversa Virtual Care and Communication Platform, streamlines patient engagement and improves health outcomes through automated, personalized messaging based on comprehensive patient profiles derived from electronic health records, biometric devices, and self-reported data. This platform enables health systems, pharmaceutical companies, and payers to shift from reactive communication to proactive engagement, facilitating better management of chronic conditions, acute discharges, and preventive care. Conversa also provides Digital Checkups, which generate tailored clinical questions and alerts based on individual patient data, and Conversa Connect, a patient profiling and health signals engine. Established in 2013 and headquartered in Portland, Oregon, with additional offices in New York, North Carolina, and California, Conversa Health serves a diverse clientele, including healthcare providers, health systems, and health technology companies.

NovaScan, Inc. is a company dedicated to the development and manufacturing of innovative cancer detection devices. Founded by the former Dean of the Engineering School at the University of Wisconsin Milwaukee, NovaScan specializes in a non-invasive detection platform that utilizes Cole relaxation frequency technology for the identification and stratification of various cancers. Its product line includes MarginScan for skin cancer detection, BiopsyScan for breast biopsy procedures, FastScan Probe for breast cancer identification, and additional technologies that facilitate electrical mammograms and the detection of multiple cancer types. The company, incorporated in 2001 and headquartered in Chicago, Illinois, focuses on improving patient outcomes and reducing healthcare costs through its rapid, accurate diagnostic solutions, which do not require extensive capital equipment or are limited by size. NovaScan's technologies are designed to enhance minimally invasive procedures and optimize therapeutic dosing within tumors, reflecting its commitment to advancing cancer care.

Dorsata, Inc. is a healthcare technology company based in Arlington, Virginia, that specializes in creating an online platform for clinical care paths. Founded in 2011, Dorsata enables healthcare providers to enhance decision-making by offering tools that allow clinicians to build, share, and implement workflows known as care pathways. These pathways are designed to improve collaboration among healthcare teams and facilitate efficient documentation and order entry. By leveraging data and best practices, Dorsata aims to transform healthcare delivery with a focus on cost reduction and quality improvement. Additionally, the company has developed a prenatal record platform that helps manage electronic health records, providing a user-friendly experience and a rules engine to create tailored care plans for patients throughout their pregnancy journey.

Castle Biosciences, Inc. is a commercial-stage biotechnology company headquartered in Friendswood, Texas, specializing in diagnostic and prognostic tests for dermatological cancers. The company develops innovative genomic tests to aid physicians and patients in making informed treatment decisions. Its flagship product, DecisionDx-Melanoma, is a multi-gene expression profile test designed to identify stage I and II melanoma patients at high risk of metastasis. Additionally, Castle Biosciences offers the DecisionDx-UM test, which assesses the risk of metastasis in patients with uveal melanoma, a rare eye cancer. The company is also advancing two proprietary tests aimed at addressing cutaneous squamous cell carcinoma and suspicious pigmented lesions, both of which represent significant clinical needs in dermatological oncology. Through its products, Castle Biosciences aims to provide personalized and actionable genomic information, thereby enhancing cancer diagnosis and management.